France’s First Ever Hobby Shop Focused on GUNPLA: BANDAI HOBBY STORE
27.7.2020 10:00:00 EEST | Business Wire | Press release
BANDAI S.A.S. (President & CEO: Susumu Hirasawa; Head office: Tour W 102, Terrasse Boieldieu 92085 Paris La Defense cedex France) of the BANDAI NAMCO Group, Manga Story SARL (President & CEO: Patrick Carosella; Head office: 13 Boulevard Voltaire, 75011 Paris, France), and BANDAI SPIRITS CO., LTD. (President & CEO: Yusuke Fukuda; Head office: Minato-ku, Tokyo) will open the BANDAI HOBBY STORE, France's first ever hobby shop centered around GUNPLA, in the central Republic district of Paris, France on July 30, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005200/en/
BANDAI HOBBY STORE interior image. It may differ in part from the actual site. (C)SOTSU・SUNRISE
The aim of the BANDAI HOBBY STORE is to expand the BANDAI SPIRITS plastic model business in Europe by offering Europe's largest selection of GUNPLA. In addition to GUNPLA and GUNDAM-related products from the BANDAI NAMCO Group, the store will also offer many other plastic models, etc. from BANDAI SPIRITS.
The central Republic district where the new store will open is home to multiple shops selling games, anime, and comics, attracting users from all around France. Manga Story, the largest shop in the area, began selling BANDAI plastic models, focused on GUNPLA, around four years ago. Discussions with the president, Mr. Carosella regarding the possibility of opening a shop specializing in plastic models had been ongoing for some time, leading to the opening of this new store in the same area.
With about 200 square meters of space on the main floor and in the basement, the store will carry about 600 different types of plastic models, including both new and conventional products. With the various GUNPLA categories organized by color for ease of understanding, and a workshop area at the back of the store where customers can try assembling the models, everyone from child to adult, beginner to expert, will find a variety of ways to enjoy plastic models, from hands-on experience to purchase.
We will use the opening of this store as an opportunity to explore the possibility of opening multiple stores in the future.
|
Store Overview |
|
|
Name: |
BANDAI HOBBY STORE |
|
Location: |
5 boulevard Voltaire, 75011 Paris, France |
|
Business hours: |
Monday-Saturday 10:00-19:30 Closed Sundays |
|
Store area: |
Approximately 200 m2 |
|
Management: |
Manga Story |
|
Admission: |
Free |
What is "GUNPLA"?
GUNPLA are plastic models based on the GUNDAM series, launched in Japan in July 1980 and celebrating their 40th anniversary this year. So far, over 700 million units have been sold: 525.8 million from the Real series, and 174.4 million from the SD series (as of the end of May 2020), making GUNPLA the biggest hit in the history of plastic models. In recent years, we have been growing our overseas market.
Image download URL: https://bit.ly/ (this URL is valid for 30 days from the date of distribution)
* The information in this press release is current as of July 27, 2020, and is subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005200/en/
Contact information
Press inquiries:
BANDAI S.A.S. Makoto Nishiyama (mnishiyama@bandai.fr)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom